Correction: HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.

Young-Ho Lee,Xiyong Liu,Fuming Qiu,Timothy R O'Connor,Yun Yen,David K Ann

DOI: https://doi.org/10.1371/journal.pone.0124853

IF: 3.7

2015-01-01

PLoS ONE

Abstract:[This corrects the article DOI: 10.1371/journal.pone.0121207.].

What problem does this paper attempt to address?

Hp1 Beta Is A Biomarker For Breast Cancer Prognosis And Parp Inhibitor Therapy (Vol 10, E0121207, 2015)

Young-Ho Lee,Xiyong Liu,Fuming Qiu,Timothy R O'Connor,Yun Yen,David K Ann

DOI: https://doi.org/10.1371/journal.pone.0124853

IF: 3.7

2015-01-01

PLoS ONE

Abstract:[This corrects the article DOI: 10.1371/journal.pone.0121207.].
Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer

Wei-Wei Zuo,Chun-Fang Zhao,Yan Li,Hai-Yan Sun,Guo-Ming Ma,Yue-Ping Liu,Shan Kang

DOI: https://doi.org/10.3389/fonc.2023.1218746

IF: 4.7

2023-06-27

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.931445.].

oncology
Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Xinyang Liu,Shukui Qin,Zhichao Wang,Jianming Xu,Jianping Xiong,Yuxian Bai,Zhehai Wang,Yan Yang,Guoping Sun,Liwei Wang,Leizhen Zheng,Nong Xu,Ying Cheng,Weijian Guo,Hao Yu,Tianshu Liu,Pagona Lagiou,Jin Li

DOI: https://doi.org/10.1186/s13045-017-0545-5

IF: 28.5

2017-01-01

Journal of Hematology & Oncology

Abstract:The original article [1] contains two errors in Table 2
Correction: Up-Regulation of 91H Promotes Tumor Metastasis and Predicts Poor Prognosis for Patients with Colorectal Cancer.

Qiwen Deng,Bangshun He,Tianyi Gao,Yuqin Pan,Huiling Sun,Yeqiong Xu,Rui Li,Houqun Ying,Feng Wang,Xian Liu,Jie Chen,Shukui Wang

DOI: https://doi.org/10.1371/journal.pone.0304249

IF: 3.7

2024-01-01

PLoS ONE

Abstract:[This corrects the article DOI: 10.1371/journal.pone.0103022.].
Correction: the Hmlh1 −93g>a Polymorphism and Risk of Ovarian Cancer in the Chinese Population

Leilei Niu,Shumin Li,Huamao Liang,Hua Li

DOI: https://doi.org/10.1371/journal.pone.0218032

IF: 3.7

2019-01-01

PLoS ONE

Abstract:[This corrects the article DOI: 10.1371/journal.pone.0135822.].
Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer

Jiangsheng Xu,Yunhua Liu,Yujing Li,Hai Wang,Samantha Stewart,Kevin Van der Jeught,Pranay Agarwal,Yuntian Zhang,Sheng Liu,Gang Zhao,Jun Wan,Xiongbin Lu,Xiaoming He

DOI: https://doi.org/10.1038/s41565-019-0417-y

IF: 38.3

2019-01-01

Nature Nanotechnology

Abstract:The Supplementary Information originally published with this Article was an older version, in which ‘IFN-γ’ was misspelled ‘INF-γ’ in Supplementary Fig. 9 and the β-Actin blot in Supplementary Fig. 13 was the wrong image. The Supplementary Information has now been replaced.
Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

Xing Bian,Xiaolin Wang,Qiuyan Zhang,Liying Ma,Guozhen Cao,Ao Xu,Jinhua Han,Jun Huang,Wenchu Lin

DOI: https://doi.org/10.3389/fonc.2023.1192526

IF: 4.7

2023-04-13

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.565820.].

oncology
Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Qitong Chen,Dengjie Ouyang,Munawar Anwar,Ning Xie,Shouman Wang,Peizhi Fan,Liyuan Qian,Gannong Chen,Enxiang Zhou,Lei Guo,Xiaowen Gu,Boni Ding,Xiaohong Yang,Liping Liu,Chao Deng,Zhi Xiao,Jing Li,Yunqi Wang,Shan Zeng,Jinhui Hu,Wei Zhou,Bo Qiu,Zhongming Wang,Jie Weng,Mingwen Liu,Yi Li,Tiegang Tang,Jianguo Wang,Hui Zhang,Bin Dai,Wuping Tang,Tao Wu,Maoliang Xiao,Xiantao Li,Hailong Liu,Lai Li,Wenjun Yi,Quchang Ouyang

DOI: https://doi.org/10.3389/fonc.2021.661128

IF: 4.7

2021-03-05

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.00811.].

oncology
Erratum to "Bifunctional Tumor-Targeted Bioprobe for Phototheranosis"

Hae Sang Park,Shinya Yokomizo,Haoran Wang,Sophia Manganiello,Hailey Monaco,Rose McDonnell,Hajin Joanne Kim,Jiyun Rho,Sung Ahn,Jason Gladstone,Harry Jung,Homan Kang,Kai Bao,Satoshi Kashiwagi,Hak Soo Choi

DOI: https://doi.org/10.34133/bmr.0036

2024-05-29

Abstract:[This corrects the article DOI: 10.34133/bmr.0002.].
HP1β is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy.

Young-Ho Lee,Xiyong Liu,Fuming Qiu,Timothy R. O'Connor,Yun Yen,David K. Ann

DOI: https://doi.org/10.1371/journal.pone.0121207

IF: 3.7

2015-01-01

PLoS ONE

Abstract:Members of the heterochromatin protein 1 family (HP1α, β and γ) are mostly associated with heterochromatin and play important roles in gene regulation and DNA damage response. Altered expression of individual HP1 subtype has profound impacts on cell proliferation and tumorigenesis. We analyzed the expression profile of HP1 family by data mining using a published microarray data set coupled with retrospective immunohistochemistry analyses of archived breast cancer biospecimens. We found that the patient group overexpressing HP1β mRNA is associated with poorly differentiated breast tumors and with a significantly lower survival rate. Immunohistochemical staining against HP1α, HP1β and HP1γ shows that respective HP1 expression level is frequently altered in breast cancers. 57.4-60.1% of samples examined showed high HP1β expression and 39.9-42.6 % of examined tumors showed no or low expression of each HP1 subtype. Interestingly, comparative analysis on HP1 expression profile and breast cancer markers revealed a positive correlation between the respective expression level of all three HP1 subtypes and Ki-67, a cell proliferation and well-known breast cancer marker. To explore the effect of individual HP1 on PARP inhibitor therapy for breast cancer, MCF7 breast cancer cells and individually HP1-depleted MCF7 cells were treated with PARP inhibitor ABT-888 with or without carboplatin. Notably, HP1β-knockdown cells are hypersensitive to the PARP inhibitor ABT-888 alone and its combination with carboplatin. In summary, while increased HP1β expression is associated with the poor prognosis in breast cancer, compromised HP1β abundance may serve as a useful predictive marker for chemotherapy, including PARP inhibitors against breast cancer.
Correction: Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC

Zi Wang,Bianying Ma,Hui Li,Xiaojuan Xiao,Weihua Zhou,Feng Liu,Bin Zhang,M. Zhu,Qin Yang,Yayue Zeng,Yang Sun,Shuming Sun,Yanpeng Wang,Yibin Zhang,Haibo Weng,Lixiang Chen,Mao Ye,X. An,Jing Liu

DOI: https://doi.org/10.18632/oncotarget.27282

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.6312.].
Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (Nature Nanotechnology, (2019), 14, 4, (388-397), 10.1038/s41565-019-0381-6)

Jiangsheng Xu,Yunhua Liu,Yujing Li,Hai Wang,Samantha Stewart,Kevin Van der Jeught,Pranay Agarwal,Yuntian Zhang,Sheng Liu,Gang Zhao,Jun Wan,Xiongbin Lu,Xiaoming He

DOI: https://doi.org/10.1038/S41565-019-0417-Y

IF: 38.3

2019-01-01

Nature Nanotechnology

Abstract:The Supplementary Information originally published with this Article was an older version, in which ‘IFN-γ’ was misspelled ‘INF-γ’ in Supplementary Fig. 9 and the β-Actin blot in Supplementary Fig. 13 was the wrong image. The Supplementary Information has now been replaced.
Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Xin Tian,Lina Wu,Min Jiang,Zhenyong Zhang,Rong Wu,Jianing Miao,Caigang Liu,Song Gao

DOI: https://doi.org/10.3389/fonc.2022.793448

IF: 4.7

2022-04-06

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.641399.].

oncology
Erratum: PD-L1 expression in colon cancer and its relationship with clinical prognosis.

Tao Shan,Shuo Chen,Tao Wu,Yi Yang,Shunle Li,Xi Chen

2022-01-01

Abstract:[This corrects the article on p. 1764 in vol. 12, PMID: 31933995.].
Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Zexi Hu,Yong Hu,Xicheng Liu,Rongwen Xi,Aiqun Zhang,Deruo Liu,Qiang Xie,Liang Chen

DOI: https://doi.org/10.18632/oncotarget.26252

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.5221.].
Corrigendum: Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer

Huijuan Liu,Honglian Tao,Hongqi Wang,Yuyan Yang,Ru Yang,Xintong Dai,Xiujuan Ding,Haidong Wu,Shuang Chen,Tao Sun

DOI: https://doi.org/10.3389/fonc.2022.830506

IF: 4.7

2022-02-24

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.619317.].

oncology
Corrigendum: Comprehensive analysis of the prognostic and immunological role of PAFAH1B in pan-cancer

Yixiao Yuan,Xiulin Jiang,Lin Tang,Juan Wang,Lincan Duan

DOI: https://doi.org/10.3389/fmolb.2024.1497296

IF: 6.113

2024-10-09

Frontiers in Molecular Biosciences

Abstract:This article is a correction to: Comprehensive Analysis of the Prognostic and Immunological Role of PAFAH1B in Pan-Cancer

biochemistry & molecular biology
Author Correction: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Han Yao,Jiang Lan,Chushu Li,Hubing Shi,Jean-Philippe Brosseau,Huanbin Wang,Haojie Lu,Caiyun Fang,Yao Zhang,Lunxi Liang,Xiaolin Zhou,Chaojun Wang,Yu Xue,Yun Cui,Jie Xu

DOI: https://doi.org/10.1038/s41551-019-0402-7

IF: 28.1

2019-04-11

Nature Biomedical Engineering

Abstract:In the version of this Article originally published, ‘palmitoyltransferase ZDHHC3 (DHHC3)’ was incorrectly referred to as an ‘acetyltransferase’ rather than an as an ‘acyltransferase’; this has now been corrected in five instances. In Fig. 3a, the label for the bottom row of the blots was mistakenly written as ‘GAPHD’; it should have read ‘GAPDH’. In the two right-most panels of Fig. 4j, the antibody labels ‘α-PD-L1’ for the reciprocal co-immunoprecipitation of DHHC3 were incorrect; they should have been ‘α-DHHC3’. These errors have been corrected in all versions of the Article.

engineering, biomedical
Correction: An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts

Qing Chen,Ziyi Weng,Yunshu Lu,Yijun Jia,Longlong Ding,Fang Bai,Meixin Ge,Qing Lin,Kejin Wu

DOI: https://doi.org/10.1371/journal.pone.0311128

IF: 3.7

2024-09-23

PLoS ONE

Abstract:[This corrects the article DOI: 10.1371/journal.pone.0168960.].
Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma

Xiaofan Hu,Mingyang Bao,Jiacheng Huang,Lin Zhou,Shusen Zheng

DOI: https://doi.org/10.3389/fonc.2020.617539

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:CORRECTION article Front. Oncol., 20 November 2020Sec. Molecular and Cellular Oncology Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.617539

Correction: HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.

Hp1 Beta Is A Biomarker For Breast Cancer Prognosis And Parp Inhibitor Therapy (Vol 10, E0121207, 2015)

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Correction: Up-Regulation of 91H Promotes Tumor Metastasis and Predicts Poor Prognosis for Patients with Colorectal Cancer.

Correction: the Hmlh1 −93g&gt;a Polymorphism and Risk of Ovarian Cancer in the Chinese Population

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer

Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Erratum to "Bifunctional Tumor-Targeted Bioprobe for Phototheranosis"

HP1β is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy.

Correction: Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (Nature Nanotechnology, (2019), 14, 4, (388-397), 10.1038/s41565-019-0381-6)

Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Erratum: PD-L1 expression in colon cancer and its relationship with clinical prognosis.

Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Corrigendum: Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer

Corrigendum: Comprehensive analysis of the prognostic and immunological role of PAFAH1B in pan-cancer

Author Correction: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Correction: An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts

Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma

Correction: the Hmlh1 −93g>a Polymorphism and Risk of Ovarian Cancer in the Chinese Population